Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS® from Major Insurance Carrier
29 mai 2024 09h00 HE
|
Helius Medical Technologies, Inc.
-- Reimbursement at $23,900, slightly below list price -- -- Represents a significant milestone toward increasing accessibility of PoNS -- NEWTOWN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Helius...
Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS
23 mai 2024 09h00 HE
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts
20 mai 2024 09h00 HE
|
Helius Medical Technologies, Inc.
-- Approval provides U.S. veterans and other U.S. government agency employees who suffer gait and balance impairment due to multiple sclerosis (MS) access to the only portable neurostimulation therapy...
Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results
13 mai 2024 16h05 HE
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
10 mai 2024 09h00 HE
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering
06 mai 2024 22h15 HE
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS®)
06 mai 2024 09h00 HE
|
Helius Medical Technologies, Inc.
-- The Centers for Medicare & Medicaid Services (CMS) released its preliminary Medicare payment determinations for the PoNS Controller and Mouthpiece -- -- Public Meeting Scheduled for May 29,...
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
24 avr. 2024 09h05 HE
|
Helius Medical Technologies, Inc.
-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke ---- Shepherd Center, a top neurorehabilitation hospital, is the...
Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
03 avr. 2024 07h05 HE
|
Helius Medical Technologies, Inc.
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) ---- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually -- ...
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
28 mars 2024 16h05 HE
|
Helius Medical Technologies, Inc.
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused...